Filing Flows › Conmed (CNMD) › Q3 2026 › vs Q2 2026
Conmed (CNMD) Q3 2026 vs Q2 2026 (quarter over quarter)
Conmed's revenue fell $7.9M (-2%) from $343M in Q2 2026 to $336M in Q3 2026. The biggest changes: General Surgery −$4.5M (-2%); Orthopedic Surgery −$3.5M (-2%). Gross margin 56.4% against 57.5% (-1.1 pts).
Conmed, Q3 2026: revenue $336M (-0.7% year over year), operating margin 11.1%, net earnings $19.8M, operating cash flow $49.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 56.4% | 57.5% | -1.1 pts |
| Operating margin | 11.1% | 10.6% | +0.5 pts |
| Net margin | 5.9% | 6.7% | -0.8 pts |
| Free cash flow margin | 13.9% | 9.9% | +4.0 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| General Surgery | $187M | $191M | −$4.5M | -2% |
| Orthopedic Surgery | $149M | $152M | −$3.5M | -2% |
| Revenue | $336M | $343M | −$7.9M | -2% |
| Gross profit | $189M | $197M | −$8.3M | -4% |
| Cost of revenue | $146M | $146M | $379K | +0.3% |
| Operating profit | $37.1M | $36.4M | $739K | +2% |
| Operating expenses | $152M | $161M | −$9.0M | -6% |
| Pre-tax earnings | $26.0M | $31.3M | −$5.3M | -17% |
| Other expense, net | $11.1M | $5.1M | $6.1M | +120% |
| Research & development | $15.6M | $15.5M | $88K | +0.6% |
| SG&A | $136M | $146M | −$9.1M | -6% |
| Net earnings | $19.8M | $23.1M | −$3.3M | -14% |
| Income tax | $6.2M | $8.3M | −$2.1M | -25% |
| Depreciation & amortization | $12.8M | $12.8M | $2K | 0% |
| Share-based compensation | $5.9M | $5.2M | $681K | +13% |
| Working capital & other | $10.9M | −$4.0M | $14.9M | — |
| Operating cash flow | $49.4M | $37.1M | $12.3M | +33% |
| Free cash flow (OCF − capex) | $46.7M | $34.2M | $12.6M | +37% |
| Capital expenditures | $2.7M | $2.9M | −$250K | -9% |
Questions
How much did Conmed's revenue grow quarter over quarter in Q3 2026?
Conmed's revenue fell $7.9M (-2%) from $343M in Q2 2026 to $336M in Q3 2026.
What drove Conmed's revenue change in Q3 2026?
General Surgery −$4.5M (-2%); Orthopedic Surgery −$3.5M (-2%).